Trial · NCT02851108

Methylene Blue Against Falciparum Malaria in Burkina Faso

NCT02851108, Phase 2, Completed, Heidelberg University; results first posted 2020-03-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Methylene Blue Against Falciparum Malaria in Burkina Faso. Trials, record NCT02851108. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02851108

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Methylene Blue Against Falciparum Malaria in Burkina Faso
NCT number: NCT02851108
Status: Completed
Phases: Phase 2
Enrollment: 100 participants, actual
Lead sponsor: Heidelberg University
Conditions: Malaria, Falciparum
Interventions: Methylene Blue, Primaquine
First posted: 2016-08-01
Last updated: 2020-03-25
Results first posted: 2020-03-25

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Haemoglobin Compared to the Baseline	7 days	Haemoglobin concentrations will be measured in the field using a HemoCue® (HemoCue® AB, Angelholm, Sweden)
Secondary	Gametocyte Prevalence	28 days	measured microscopically at baseline and on day 1, 2, 3, 7, 14, and 28 of follow-up
Secondary	Adverse Events (AE)	28 days	Reports of observed or self-reported adverse event
Secondary	Mothers/Caretakers Questionnaire on Acceptance	14 days	Acceptance of the different treatment regimens by mothers/caretakers
Secondary	Gametocyte Density	28 days	measured microscopically at baseline and on day 1, 2, 3, 7, 14, and 28 of follow-up

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in Haemoglobin Compared to the Baseline	7 days	g/dl	MEAN
SECONDARY	Gametocyte Prevalence	28 days
SECONDARY	Adverse Events (AE)	28 days
SECONDARY	Mothers/Caretakers Questionnaire on Acceptance	14 days
SECONDARY	Gametocyte Density	28 days

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in Haemoglobin Compared to the Baseline	AS-AQ-MB		0.18	Standard Deviation 1.42	g/dl
Change in Haemoglobin Compared to the Baseline	AS-AQ-PQ		0.54	Standard Deviation 0.94	g/dl

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	AS-AQ-MB	50
Overall Study	STARTED	AS-AQ-PQ	50
Overall Study	COMPLETED	AS-AQ-MB	42
Overall Study	COMPLETED	AS-AQ-PQ	49
Overall Study	NOT COMPLETED	AS-AQ-MB	8
Overall Study	NOT COMPLETED	AS-AQ-PQ	1

Source ClinicalTrials.gov

Adverse events8

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Gastro-intestinal symptoms	Gastrointestinal disorders	AS-AQ-MB	14	50	19
other	Gastro-intestinal symptoms	Gastrointestinal disorders	AS-AQ-PQ	13	50	16
other	Respiratory symptoms	Respiratory, thoracic and mediastinal disorders	AS-AQ-MB	20	50	25
other	Respiratory symptoms	Respiratory, thoracic and mediastinal disorders	AS-AQ-PQ	20	50	35
serious	Severe anemia	Blood and lymphatic system disorders	AS-AQ-MB	1	50	1
serious	Severe anemia	Blood and lymphatic system disorders	AS-AQ-PQ	0	50	0
serious	Severe malaria	Infections and infestations	AS-AQ-MB	1	50	1
serious	Severe malaria	Infections and infestations	AS-AQ-PQ	0	50	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	AS-AQ-MB
Total, all-cause mortality	AS-AQ-PQ
Total, other adverse events	AS-AQ-MB	33	50
Total, other adverse events	AS-AQ-PQ	28	50
Total, serious adverse events	AS-AQ-MB	2	50
Total, serious adverse events	AS-AQ-PQ	0	50

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
31600221	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
AS-AQ-MB vs AS-AQ-PQ: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02851108

GET https://conductscience.org/api/trials/v1/NCT02851108/registered

API reference For AI assistants